Showing 1 - 3 results of 3 for search 'F. Buadi', query time: 0.02s Refine Results
  1. 1
    P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP

    P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP by N. Abdallah, A. Dispenzieri, E. Muchtar, F. Buadi, P. Kapoor, M. Lacy, Y. Hwa, A. Fonder, M. Hobbs, S. Hayman, N. Leung, D. Dingli, R. Go, Y. Lin, W. Gonsalves, M. Binder, T. Kourelis, R. Warsame, R. Kyle, S. Rajkumar, M. Gertz, S. Kumar

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE

    P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE by I. Vaxman, S. Kumar, F. buadi, M. Lacy, D. Dingli, A. Fonder, M. Hobbs, S. Hayman, L. Y. hwa, T. Kouralis, R. Warsame, E. Muchtar, L. Nelson, P. Kapoor, M. Grogan, R. Go, W. Gonsalves, M. Siddiqi, K. Robert, V. Rajkumar, M. Gertz, A. Dispenzieri

    Published 2022-06-01
    Get full text
    Article
  3. 3
    Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

    Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience by I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, S. Hayman, T. Kourelis, R. Warsame, Y. Hwa, A. Fonder, M. Hobbs, E. Muchtar, N. Leung, P. Kapoor, R. Go, Y. Lin, W. Gonsalves, M. Siddiqui, R. A. Kyle, S. V. Rajkumar, M. A. Gertz, A. Dispenzieri

    Published 2023-05-01
    Get full text
    Article

Search Tools: